FTC Review Of Express Scripts/Medco Merger Is First Integration Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
The proposed merger of two of the three major pharmacy benefit managers may have tough time clearing FTC; the agency has rejected other deals that would have left only two dominant players in a sector.
You may also be interested in...
Express Scripts/Medco Merger's Impact On Small Pharmacies Is Focus Of Hearing
Express Scripts CEO tells House Judiciary subcommittee that the companies would not be in favor of divesting their mail order and specialty pharmaceutical businesses.
Express Scripts/Medco Merger's Impact On Small Pharmacies Is Focus Of Hearing
Express Scripts CEO tells House Judiciary subcommittee that the companies would not be in favor of divesting their mail order and specialty pharmaceutical businesses.
Express Scripts/Medco Merger Faces Longer Odds After FTC's Second Request
Following the Federal Trade Commission’s second request for additional information about Express Scripts Inc.'s proposed acquisition of Medco Health Solutions Inc., it is now statistically likely that the deal will be blocked or subject to a divestiture.